1. Home
  2. News Archive

More News

Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports
Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports

Private insurers involved in the US Medicare Advantage program added hundreds of thousands of questionable diagnoses, including those for diabetic cataracts, to patient records in recent years to b...

MST Offers Diamond Knife Subscription Service in Move to Curb Waste
MST Offers Diamond Knife Subscription Service in Move to Curb Waste

MicroSurgical Technology (MST) has launched a diamond knife subscription service for US ophthalmologists. The Redmond, Washington, company kicked off the service in April at the 2024 meeting of the...

Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101

Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...

Genentech to Reintroduce Susvimo for Wet AMD, Ending Voluntary Recall
Genentech to Reintroduce Susvimo for Wet AMD, Ending Voluntary Recall

Genentech, a member of the Roche Group, announced July 8 that it was reintroducing Susvimo, a refillable ranibizumab intravitreal implant for wet age-related macular degeneration (AMD) in the US, e...

US FDA Approves Vabysmo Prefilled Syringe for Wet AMD, DME, and RVO Indications
US FDA Approves Vabysmo Prefilled Syringe for Wet AMD, DME, and RVO Indications

Genentech, a member of the Roche Group, announced July 5 that the US FDA had approved the Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe for wet age-related macular degeneration (AMD...

Weekly Surgeon Poll, July 2024
Weekly Surgeon Poll, July 2024

July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

EssilorLuxottica Acquires Majority Stake in Diagnostics Maker Heidelberg
EssilorLuxottica Acquires Majority Stake in Diagnostics Maker Heidelberg 

Eyewear conglomerate EssilorLuxottica announced July 17 that it had agreed to acquire an 80 percent stake in Heidelberg Engineering, a leader in ophthalmic diagnostic imaging. Financial details wer...

Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101

Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...

Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports
Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports

Private insurers involved in the US Medicare Advantage program added hundreds of thousands of questionable diagnoses, including those for diabetic cataracts, to patient records in recent years to b...

J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million
J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million

J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...

Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications
Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications

Beacon Therapeutics will evaluate Abeona Therapeutics’ patented AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 11. AAV204, a novel AAV ca...

NexThera Files IND with US FDA for Trial of Wet AMD Eye Drop Candidate
NexThera Files IND with US FDA for Trial of Wet AMD Eye Drop Candidate

NexThera, of Busan, South Korea, announced July 16 that it had filed an investigational new drug (IND) application with the US FDA for a Phase I/IIa trial of NT-101, an eye drop candidate for wet a...

Ophthalmic Chain in Colorado Closing All Six Clinics, Citing COVID-19 Financial Fallout
Ophthalmic Chain in Colorado Closing All Six Clinics, Citing COVID-19 Financial Fallout

Rocky Mountain Eye Center, based in Pueblo, Colorado, announced on its website that it will close all of its six clinics on July 31, saying the practice was unable to recover from the financial fal...

Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain

London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...

Eyenuk Appoints Bryan Haardt as Chief Executive Officer
Eyenuk Appoints Bryan Haardt as Chief Executive Officer

Digital health care company Eyenuk, of Los Angeles, California, announced July 18 that it had appointed Bryan Haardt as chief executive officer. Paul Praino, who had been serving as Eyenuk’s interi...

Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer
Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer

Sydnexis, of Del Mar, California, announced July 16 that Perry J. Sternberg had been appointed chief executive officer and as a member of the board of directors. He will join the company on Aug. 5,...

UK Regulators Approve Outlook’s Lytenava (Bevacizumab) for Wet AMD
UK Regulators Approve Outlook’s Lytenava (Bevacizumab) for Wet AMD

Outlook Therapeutics announced July 8 that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) had granted marketing authorization for Lytenava, an ophthalmic formulation of bevaciz...

Ophthalmic Devices to be Included in FDA TAP Program
Ophthalmic Devices to be Included in FDA TAP Program

The US FDA announced July 1 that it was expanding its TAP pilot program in October to include ophthalmic devices, as well as radiological health devices. The voluntary program, officially named the...

US FDA Approves Vabysmo Prefilled Syringe for Wet AMD, DME, RVO
US FDA Approves Vabysmo Prefilled Syringe for Wet AMD, DME, RVO

Genentech, a member of the Roche Group, announced July 5 that the US FDA had approved the Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe for wet age-related macular degeneration (AMD...

Genentech to Reintroduce Susvimo for Wet AMD, Ending Voluntary Recall
Genentech to Reintroduce Susvimo for Wet AMD, Ending Voluntary Recall

Genentech, a member of the Roche Group, announced July 8 that it was reintroducing Susvimo, a refillable ranibizumab intravitreal implant for wet age-related macular degeneration (AMD) in the US, e...

Ophthalmology Chain Clínica Baviera Enters UK Market with Acquisition of Optimax
Ophthalmology Chain Clínica Baviera Enters UK Market with Acquisition of Optimax

European ophthalmology chain Clínica Baviera has extended its reach into the UK with the purchase of Optimax. Optimax (Eye Hospitals Group and subsidiaries) operates 19 clinics under the Optimax an...

Altos Biologics Files for European Approval of Aflibercept (Eylea) Biosimilar
Altos Biologics Files for European Approval of Aflibercept (Eylea) Biosimilar

Altos Biologics has submitted a marketing authorization application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept (Eylea) biosimilar, according to a joint announcement by Altos ...

China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME
China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME

China’s DP Technology announced July 8 that it would advance DPT0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a potential oral treatment candidate for...

Market Scope Appoints Kristen Harmon Ingenito as CEO
Market Scope Appoints Kristen Harmon Ingenito as CEO

ST. LOUIS, Mo. July 11, 2024 – Market Scope, the global ophthalmic market research partner of industry and medical professionals, is pleased to announce the appointment of Kristen Harmon Ingenito, ...

Alkeus Appoints Michel Dahan as President and CEO
Alkeus Appoints Michel Dahan as President and CEO

Alkeus Pharmaceuticals announced July 2 that Michel Dahan had joined the company as president and chief executive officer. He had served as a member of the board since January 2023. Alkeus, of Camb...

IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Nod for Marketing
IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Nod for Marketing

Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...

US FDA Approves Aflibercept (Eylea) Biosimilar from Formycon, Klinge
US FDA Approves Aflibercept (Eylea) Biosimilar from Formycon, Klinge

German companies Formycon and Klinge Biopharma announced June 28 that the US FDA had approved their aflibercept (Eylea) biosimilar for wet age-related macular degeneration (AMD), diabetic macular e...

J&J Leads Series A Round for Crosslinking Tech Developer TecLens
J&J Leads Series A Round for Crosslinking Tech Developer TecLens

Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...

Roche’s Vabysmo Gains Positive CHMP Opinion in EU for Third Indication—RVO
Roche’s Vabysmo Gains Positive CHMP Opinion in EU for Third Indication—RVO

Swiss drugmaker Roche announced June 28 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended the extension of Vabysmo’s labeling to include tre...

Blinking Boosts Visual Perception Rather than Hindering It, Study Shows
Blinking Boosts Visual Perception Rather than Hindering It, Study Shows

Researchers at the University of Rochester have found that blinking plays a critical role in visual perception, in addition to maintaining eye health. Their research was published in April 2024 in ...

US FDA Grants Breakthrough, Regenerative Medicine Status to Aurion’s Corneal Cell Therapy Candidate
US FDA Grants Breakthrough, Regenerative Medicine Status to Aurion’s Corneal Cell Therapy Candidate

Aurion Biotech announced June 19 that the US FDA had granted both breakthrough therapy and regenerative medicine advanced therapy status for AURN001, the company’s allogeneic cell therapy candidate...

Kane Biotech Licenses Biofilm Dispersion Enzyme to I-Med for Dry Eye
Kane Biotech Licenses Biofilm Dispersion Enzyme to I-Med for Dry Eye

Kane Biotech announced June 25 that I-Med Pharma had licensed its DispersinB biofilm dispersion technology to incorporate into its products to relieve dry eye. It’s the first commercial agreement f...

RevOpsis Enlists India’s Kemwell Biopharma to Manufacture Wet AMD Candidate
RevOpsis Enlists India’s Kemwell Biopharma to Manufacture Wet AMD Candidate

RevOpsis Therapeutics, of San Carlos, California, announced June 17 that it had entered into a strategic manufacturing partnership with India’s Kemwell Biopharma. The deal aims to accelerate develo...

Alcon Gains US FDA 510(k) Clearance for Unity VCS and CS Systems
Alcon Gains US FDA 510(k) Clearance for Unity VCS and CS Systems

Alcon reported June 24 that itsUnity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) had received US FDA 510(k) clearance. The company said it would be seeking real-world feedbac...

ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million

ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 million up front. The deal is expected to close in late Q3-2024, the c...

Harrow Looks to Relaunch Triesence in 2024, as Production Testing Continues
Harrow Looks to Relaunch Triesence in 2024, as Production Testing Continues

Nashville, Tennessee-based Harrow reported June 20 that it was moving closer to relaunching Triesence in 2024 after successfully achieving a production testing milestone. Triesence (triamcinolone a...

US FDA Accepts BLA for Neurotech’s MacTel Candidate, Grants Priority Review
US FDA Accepts BLA for Neurotech’s MacTel Candidate, Grants Priority Review

Neurotech Pharmaceuticals announced June 20 that the US FDA had accepted its biologic license application (BLA) and granted priority review for NT-501, an encapsulated cell therapy implant candidat...

Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA
Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA

Vyluma announced June 18 that it had met with the US FDA’s Division of Ophthalmology to discuss resubmitting its new drug application (NDA) for lead compound NVK002, a low-dose formulation of atrop...

US FDA Gives Green Light to Trial of 4DMT’s Gene Therapy Candidate for GA
US FDA Gives Green Light to Trial of 4DMT’s Gene Therapy Candidate for GA

4D Molecular Therapeutics announced June 24 that the US FDA had cleared its investigational new drug application for a Phase I clinical trial of 4D-175, an intravitreal gene therapy candidate targe...

CMS Winding Down Funding Program to Address Change Healthcare Cyberattack
CMS Winding Down Funding Program to Address Change Healthcare Cyberattack

The Centers for Medicare and Medicaid Services announced June 17 that funding it made available to health care providers under the Change Healthcare/Optum Payment Disruption (CHOPD) program would e...

Evolution Optiks Receives US FDA 510(k) Clearance for Tele-refactor
Evolution Optiks Receives US FDA 510(k) Clearance for Tele-refactor

Barbados-based Evolution Optiks announced June 4 that it had received 510(k) clearance from the US FDA for the LFR-260, its light field powered subjective tele-refractor. The device gained CE marki...

Volume-Based Procurement Could Upend China’s IOL Market
Volume-Based Procurement Could Upend China’s IOL Market

Alcon offered big discounts in China’s public sector centralized volume-based procurement (VBP) cycle for intraocular lenses (IOLs). The company’s low bids in seven of the eight bidding categories ...

Eye Banking Meeting Celebrates Successful Transplants, Looks at Needs Going Forward
Eye Banking Meeting Celebrates Successful Transplants, Looks at Needs Going Forward

Attendees at the 2024 Eye Banking Association of America (EBAA) meeting celebrated many achievements and milestones across the eye banking profession and transplant community in general, as 2023 ma...

Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume
Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.0 percent in Q1-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

Ophthalmic Company Revenue Totals $11 Billion, a Drop of 0.2 Percent, in Q1-2024
Ophthalmic Company Revenue Totals $11 Billion, a Drop of 0.2 Percent, in Q1-2024

Ophthalmic manufacturer revenue in Q1-2024 totaled $11.0 billion. Revenue decreased 0.2 percent from the same quarter in 2023 and dropped 1.7 percent from Q4-2023. The total includes Market Scope e...

Innovations on Horizon are Expected to Rejuvenate Cataract Equipment Market
Innovations on Horizon are Expected to Rejuvenate Cataract Equipment Market

Signs of innovation and renewal can be found in all segments of the cataract equipment market, despite evidence that the market has become mature. Innovation looms in next-generation ultrasonic pha...

Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity

Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...

EU Regulators Approve Outlook’s Lytenava (Bevacizumab) for Wet AMD
EU Regulators Approve Outlook’s Lytenava (Bevacizumab) for Wet AMD

Outlook Therapeutics announced May 28 that the European Commission had granted marketing authorization for Lytenava, an ophthalmic formulation of bevacizumab for the treatment of wet age-related ma...

Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in US
Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in US

Nordic Pharma announced May 29 that it had launched Lacrifill canalicular gel for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative intended to temporarily block tear draina...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more